This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Hypertension  • Alert me on articles by topic

Should They Be Revised?

Arch Intern Med. 1999;159:1403-1406.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

SINCE PUBLICATION of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) in the November 24, 1997, issue of the ARCHIVES,¹ several long-term morbidity and mortality trials and several comparative medication studies have been published. It is of interest to review the rationale for the JNC VI recommendations and discuss possible revisions that may be indicated on the basis of data from these new trials.

RECOMMENDATIONS FOR INITIAL THERAPY

The 1997 committee suggested that if lifestyle modifications, which included weight loss if appropriate, moderation of sodium and alcohol intake, moderate exercise, and cessation of smoking, were not effective in reducing blood pressure to a goal level of less than 140/90 mm Hg or to even lower levels in persons with diabetes or renal failure, specific antihypertensive medication should be started. The time for lifestyle modification varied according to the level of risk. Those . . . [Full Text of this Article]

WHY DIURETICS OR -BLOCKERS AS INITIAL THERAPY?

DO RESULTS OF THE NEW TRIALS SINCE 1996-1997 SUGGEST A CHANGE IN JNC VI RECOMMENDATIONS?

The Syst-Eur Trial in the Elderly

The Verapamil in Hypertension Atherosclerosis Study

The Hypertension Optimum Treatment (HOT) Study

CONFLICTING RESULTS IN HYPERTENSIVE SUBJECTS WITH TYPE 2 DIABETES MELLITUS

THE CAPTOPRIL PREVENTION PROJECT

COMPARATIVE DATA WITH ACE I AND CALCIUM CHANNEL BLOCKERS

ARE THERE DATA ON THE ANGIOTENSIN II RECEPTOR BLOCKERS?

SHOULD RECOMMENDATIONS BE CHANGED?

CONCLUSIONS

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Translating Research into Practice: Are Physicians Following Evidence-Based Guidelines in the Treatment of Hypertension?
Holmes et al.
Med Care Res Rev 2004;61:453-473.
ABSTRACT  

National Guidelines, Clinical Trials, and Quality of Evidence
Psaty et al.
Arch Intern Med 2000;160:2577-2580.
FULL TEXT  

The Urgent Need to Improve Hypertension Care
Trilling and Froom
Arch Fam Med 2000;9:794-801.
ABSTRACT | FULL TEXT